Advertisement
Screener

Reviva Pharmaceuticals Holdings, Inc. (RVPH) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Reviva Pharmaceuticals Holdings, Inc. Operating Cash Flow

Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Operating Cash Flow of -$5.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12

  • Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$2.12M.
  • Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$3.80M.
  • Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.80M.
  • Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$5.59M.
  • Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$24.59M.
  • Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$33.54M.
  • Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$28.32M.
  • Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$18.96M.
Period endNet Cash Provided by (Used in) Operating Activities 2 monthNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 5 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 8 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 11 monthNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$2.12M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$5.92M
10-Q · filed 2026-08-12
-$11.71M
derived: sum of 3 quarters · filed 2026-08-12
-$17.30M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31-$3.80M
10-Q · filed 2026-05-13
-$9.60M
derived: sum of 2 quarters · filed 2026-05-13
-$15.19M
derived: sum of 3 quarters · filed 2026-05-13
-$20.20M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31-$5.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
-$11.39M
derived: sum of 2 quarters · filed 2026-03-30
-$16.40M
derived: sum of 3 quarters · filed 2026-08-12
-$24.59M
10-K · filed 2026-03-30
2025-09-30-$5.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$10.60M
derived: sum of 2 quarters · filed 2026-08-12
-$18.80M
10-Q · filed 2025-11-13
-$27.90M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30-$5.01M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$13.21M
10-Q · filed 2026-08-12
-$22.31M
derived: sum of 3 quarters · filed 2026-08-12
-$26.55M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31-$8.19M
10-Q · filed 2026-05-13
-$17.29M
derived: sum of 2 quarters · filed 2026-05-13
-$21.54M
derived: sum of 3 quarters · filed 2026-05-13
-$30.01M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31-$9.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
-$13.34M
derived: sum of 2 quarters · filed 2026-03-30
-$21.82M
derived: sum of 3 quarters · filed 2026-03-30
-$33.54M
10-K · filed 2026-03-30
2024-09-30-$4.24M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$12.72M
derived: sum of 2 quarters · filed 2025-11-13
-$24.44M
10-Q · filed 2025-11-13
-$33.32M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$8.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
-$20.20M
10-Q · filed 2025-08-14
-$29.08M
derived: sum of 3 quarters · filed 2025-08-14
-$35.26M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$11.73M
10-Q · filed 2025-05-15
-$20.60M
derived: sum of 2 quarters · filed 2025-05-15
-$26.78M
derived: sum of 3 quarters · filed 2025-05-15
-$32.10M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31-$8.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-03
-$15.06M
derived: sum of 2 quarters · filed 2025-04-03
-$20.37M
derived: sum of 3 quarters · filed 2025-04-03
-$28.32M
10-K · filed 2025-04-03
2023-09-30-$6.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
-$11.50M
derived: sum of 2 quarters · filed 2024-11-14
-$19.45M
10-Q · filed 2024-11-14
-$24.14M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30-$5.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
-$13.27M
10-Q · filed 2024-08-14
-$17.96M
derived: sum of 3 quarters · filed 2024-08-14
-$21.96M
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31-$7.95M
10-Q · filed 2024-05-14
-$12.64M
derived: sum of 2 quarters · filed 2024-05-14
-$16.64M
derived: sum of 3 quarters · filed 2024-05-14
-$20.65M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31-$4.69M
derived: 10-K 12 month − 10-K 9 month · filed 2024-04-15
-$8.69M
derived: sum of 2 quarters · filed 2024-04-15
-$12.69M
derived: sum of 3 quarters · filed 2024-04-15
-$18.96M
10-K · filed 2024-04-15
2022-09-30-$4.00M
derived: 10-K 9 month − 10-Q 6 month · filed 2024-04-15
-$8.00M
derived: sum of 2 quarters · filed 2024-04-15
-$14.27M
10-K · filed 2024-04-15
-$18.17M
derived: sum of 4 quarters · filed 2024-04-15
2022-06-30-$4.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
-$10.27M
10-Q · filed 2023-08-14
-$14.17M
derived: sum of 3 quarters · filed 2023-08-14
-$16.48M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31-$6.27M
10-Q · filed 2023-05-15
-$10.17M
derived: sum of 2 quarters · filed 2023-05-15
-$12.48M
derived: sum of 3 quarters · filed 2023-05-15
-$13.82M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31-$3.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
-$6.21M
derived: sum of 2 quarters · filed 2023-03-30
-$7.55M
derived: sum of 3 quarters · filed 2023-03-30
-$10.67M
10-K · filed 2023-03-30
2021-09-30-$2.31M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
-$3.65M
derived: sum of 2 quarters · filed 2022-11-14
-$6.77M
10-Q · filed 2022-11-14
-$9.70M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$1.34M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
-$4.46M
10-Q · filed 2022-08-15
-$7.39M
derived: sum of 3 quarters · filed 2022-08-15
2021-03-31-$3.12M
10-Q · filed 2022-05-16
-$6.05M
derived: sum of 2 quarters · filed 2022-05-16
2020-12-31-$2.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15
-$4.07M
10-K · filed 2022-03-15
-$3.73M
10-K · filed 2021-03-22
2020-11-30-$213.69K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-01-14
-$520.76K
10-Q · filed 2021-01-14
2020-09-30-$715.64K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
-$1.13M
10-Q · filed 2021-11-15
2020-08-31-$271.61K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-10-14
-$307.06K
10-Q · filed 2020-10-14
2020-06-30-$354.73K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16
-$415.39K
10-Q · filed 2021-08-16
2020-05-31-$35.46K
10-Q · filed 2020-07-07
2020-03-31-$60.66K
10-Q · filed 2021-05-17
2020-02-29-$247.85K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-04
-$324.78K
derived: sum of 2 quarters · filed 2021-01-14
-$387.23K
derived: sum of 3 quarters · filed 2021-01-14
-$426.59K
10-K · filed 2020-05-04
2019-12-31-$218.44K
10-K/A · filed 2021-05-07
2019-11-30-$76.93K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-01-14
-$139.38K
derived: sum of 2 quarters · filed 2021-01-14
-$178.74K
10-Q · filed 2021-01-14
2019-08-31-$62.45K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-10-14
-$101.81K
10-Q · filed 2020-10-14
2019-05-31-$39.36K
10-Q · filed 2020-07-07
2019-02-28-$220.87K
10-K · filed 2020-05-04
2018-11-30-$132.96K
10-Q · filed 2020-01-10
2018-08-31-$92.35K
10-Q · filed 2019-10-08
2018-05-31$11.66K
10-Q · filed 2019-07-03

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
REVELATION BIOSCIENCES, INC. (REVB)United States$0.004B
HCW Biologics Inc. (HCWB)United States$0.004B-6.15
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06